APSR2026-743

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP11-016
P58
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1221178-46904-APSR26_AP11-016_Poster Myanmar (Final)_437192.pdf
Format: PDF Only
09. Asthma
5

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Prof. Yadanar Kyaw * President, Myanmar Thoracic Society Sr Consultant Pulmonologist Myanmar Myanmar (Burma)
Pushplata Kadam - Cipla Ltd Global Medical affairs Mumbai India
Anniruddha Mukhopadhyay - Cipla Ltd Global Medical affairs Mumbai India
Jaideep Gogtay - Cipla Ltd Global Medical affairs Mumbai India
Vaibhav Gaur - Cipla Ltd Global Medical affairs Mumbai India
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Prof. Yadanar
Kyaw
pushuchougule@gmail.com
+919969415681
41-50
 
Original Research
Perception of clinicians on Asthma management in Myanmar
Maximum 25 words
Abstract Content
This survey aimed to understand asthma management practices in Myanmar by assessing clinicians’ perceptions, prescribing patterns, and treatment preferences across different asthma severities.
A cross-sectional, questionnaire-based survey was conducted among 72 clinicians from 15 cities across Myanmar, comprising physicians, general practitioners, and chest physician.
Clinicians reported an equal distribution of patients across mild asthma (Global Initiative for Asthma [GINA] Steps 1–2) and moderate‑to‑severe asthma (GINA Steps 3–5). Treatment decisions were mainly influenced by global guideline recommendations (49%), continuing medical education (CME) activities (44%), and accumulated clinical experience (44%). For mild asthma, as‑needed low‑dose inhaled corticosteroid/formoterol (ICS/formoterol) was the preferred reliever (54%) and controller (53%). In GINA Steps 3–5, ICS/formoterol‑based regimens were selected by 67% of clinicians, with a clear preference for pressurized metered‑dose inhalers (pMDIs) over dry‑powder inhalers (DPIs). Most clinicians (94%) supported initiating low‑dose ICS in Step 1, consistent with GINA recommendations. Additionally, 96% emphasized that appropriate inhaler device selection is essential for improving adherence. About 65% of patients were able to use budesonide/formoterol as maintenance‑and‑reliever therapy (MART). Clinicians highlighted device selection as a key determinant of adherence, guided primarily by robust clinical evidence (53%) and user‑friendly inhaler design (49%). Despite adherence‑focused efforts, around 18% of patients, particularly those with mild asthma, were perceived to have inhibition toward initiating inhaled therapy. Regular follow‑up visits (55%) and patient education materials (36%) were the most frequently used strategies to strengthen adherence and reduce treatment hesitancy.
Clinicians in Myanmar demonstrate strong adherence to guideline-based asthma management, with a consistent preference for ICS/formoterol across disease severities and good awareness of updated GINA recommendations. However, challenges related to inhaler acceptance and sustained adherence persist, emphasizing the need for enhanced patient education and individualized device selection to optimize treatment outcomes.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
GINA steps, ICS/formoterol, Inhaler technique
maximum 3 keywords and no abbreviations, separated by commas
 
306